Literature DB >> 18549522

Galectins: structure, function and therapeutic potential.

Ri-Yao Yang1, Gabriel A Rabinovich, Fu-Tong Liu.   

Abstract

Galectins are a family of animal lectins that bind beta-galactosides. Outside the cell, galectins bind to cell-surface and extracellular matrix glycans and thereby affect a variety of cellular processes. However, galectins are also detectable in the cytosol and nucleus, and may influence cellular functions such as intracellular signalling pathways through protein-protein interactions with other cytoplasmic and nuclear proteins. Current research indicates that galectins play important roles in diverse physiological and pathological processes, including immune and inflammatory responses, tumour development and progression, neural degeneration, atherosclerosis, diabetes, and wound repair. Some of these have been discovered or confirmed by using genetically engineered mice deficient in a particular galectin. Thus, galectins may be a therapeutic target or employed as therapeutic agents for inflammatory diseases, cancers and several other diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18549522     DOI: 10.1017/S1462399408000719

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  263 in total

1.  The thymus microenvironment in regulating thymocyte differentiation.

Authors:  Jacy Gameiro; Patrícia Nagib; Liana Verinaud
Journal:  Cell Adh Migr       Date:  2010-07-15       Impact factor: 3.405

Review 2.  Towards molecular mechanisms regulating the expression of galectins in cancer cells under microenvironmental stress conditions.

Authors:  Alexander V Timoshenko
Journal:  Cell Mol Life Sci       Date:  2015-08-06       Impact factor: 9.261

Review 3.  Does cirrhotic cardiomyopathy exist? 50 years of uncertainty.

Authors:  Pierpaolo Pellicori; Concetta Torromeo; Angela Calicchia; Alessandra Ruffa; Martina Di Iorio; John G F Cleland; Manuela Merli
Journal:  Clin Res Cardiol       Date:  2013-09-01       Impact factor: 5.460

Review 4.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 5.  Expanding the universe of cytokines and pattern recognition receptors: galectins and glycans in innate immunity.

Authors:  Juan P Cerliani; Sean R Stowell; Iván D Mascanfroni; Connie M Arthur; Richard D Cummings; Gabriel A Rabinovich
Journal:  J Clin Immunol       Date:  2010-12-24       Impact factor: 8.317

Review 6.  Biochemical markers of aging for longitudinal studies in humans.

Authors:  Peter M Engelfriet; Eugène H J M Jansen; H Susan J Picavet; Martijn E T Dollé
Journal:  Epidemiol Rev       Date:  2013-02-04       Impact factor: 6.222

7.  Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease.

Authors:  Casey M Rebholz; Elizabeth Selvin; Menglu Liang; Christie M Ballantyne; Ron C Hoogeveen; David Aguilar; John W McEvoy; Morgan E Grams; Josef Coresh
Journal:  Kidney Int       Date:  2017-08-31       Impact factor: 10.612

8.  NMR and MD investigations of human galectin-1/oligosaccharide complexes.

Authors:  Christophe Meynier; Mikael Feracci; Marion Espeli; Florence Chaspoul; Philippe Gallice; Claudine Schiff; Françoise Guerlesquin; Philippe Roche
Journal:  Biophys J       Date:  2009-12-16       Impact factor: 4.033

Review 9.  Synthetic glycoconjugates inhibitors of tumor-related galectin-3: an update.

Authors:  Vanessa Leiria Campo; Marcelo Fiori Marchiori; Lílian Cataldi Rodrigues; Marcelo Dias-Baruffi
Journal:  Glycoconj J       Date:  2016-08-15       Impact factor: 2.916

10.  Differential transcriptomic responses of Biomphalaria glabrata (Gastropoda, Mollusca) to bacteria and metazoan parasites, Schistosoma mansoni and Echinostoma paraensei (Digenea, Platyhelminthes).

Authors:  Coen M Adema; Patrick C Hanington; Cheng-Man Lun; George H Rosenberg; Anthony D Aragon; Barbara A Stout; Mara L Lennard Richard; Paul S Gross; Eric S Loker
Journal:  Mol Immunol       Date:  2009-12-03       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.